摘要
目的探讨紫杉醇+顺铂化疗及适形调强放射技术联合贝伐单抗治疗Ⅲ期Ⅳ期宫颈癌患者的临床疗效.方法将114例Ⅲ/Ⅳ期宫颈癌患者采用随机数字表法分为观察组和对照组,每组57例.对照组予以紫杉醇+顺铂化疗及适形调强放射技术治疗,观察组在对照组基础上予以贝伐单抗治疗.21d为1个周期,观察3个周期.治疗前后检测两组血清血管内皮生长因子、癌胚抗原、人鳞状细胞癌抗原水平变化,采用生活质量核心问卷评估两组生活质量,比较两组总有效率、临床控制率及不良反应发生率.结果治疗3个周期后观察组血清血管内皮生长因子、癌胚抗原、人鳞状细胞癌抗原水平均显著低于对照组(P<0.01),生活质量核心问卷各维度评分均显著高于对照组(P<0.01),总有数率(59.7%)、临床控制率(89.5%)显著高于对照组(31.6%、68.4%)(P<0.01),各种不良反应发生率与对照组比较差异无统计学意义(P>0.05).结论紫杉醇+顺铂化疗及适形调强放射技术联合贝伐单抗治疗Ⅲ期Ⅳ期宫颈癌患者具有协同增效作用,疗效显著,能降低血清血管内皮生长因子、癌胚抗原、人鳞状细胞癌抗原水平,提高患者生活质量,安全性高.
Objective To analyze the clinical effect of paclitaxel+cisplatin(TP)chemotherapy and conformal intensity modulated radiation(IMRT)combined with bevacizumab in the treatment of stage Ⅲ/Ⅳ cervical cancer.Methods A total of 114 patients with stage Ⅲ/Ⅳ cervical cancer were randomly divided into observation group and control group,57 cases each.The control group was treated with TP chemotherapy and IMRT,and the observation group was treated with bevacizumab on the basis of the control group.21 d was 1 cycle,and observed 3 cycles.Changes in serum vascular endothelial growth factor,CEA,and SCC-Ag levels were measured before and after treatment in both groups.QLQ-C30 was used to evaluate the quality of life of the two groups,and the total effective rate,clinical control rate and incidence of adverse reactions were compared between the two groups.Results After 3 cycles of treatment,the serum VEGF,CEA,and SCC-Ag levels in the observation group were significantly lower than those in the control group(P<0.01),and the QLQ C30 scores in all dimensions were significantly higher than those in the control group(P<0.01).The total efctive rate(59.7%)and clinical control rate(89.5%)were significantly higher than those of the control group(31.6%,68.4%)(P<0.01).There was no significant difference in the incidence of various adverse reactions compared with the control group(P>0.05).Conclusions TP chemotherapy and IMRT combined with bevacizumab in the treatment of stage Ⅲ/Ⅳ cervical cancer has significant curative effect,which can reduce serum VEGF,CEA and SCC-Ag levels,improve patients'quality of life and has high safety.
作者
董雪
王燕
黄冬梅
Dong Xue;Wang Yan;Huang Dongmei(Second Affiliated Hospital of Zhengzhou Universily,Zhengzhou 450000,Henan,China)
出处
《临床心身疾病杂志》
CAS
2020年第2期52-56,共5页
Journal of Clinical Psychosomatic Diseases
